drugset / Trial / NCT01889251
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
Timeline
- Start
- 2013-07
- Primary completion
- 2014-09
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ocriplasmin | Protein / enzyme biologic | 125 ug | Intravitreal |